Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ILEVRO

« Back to Dashboard
Ilevro is a drug marketed by Alcon Res Ltd and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.

This drug has eigthy-five patent family members in twenty-five countries.

The generic ingredient in ILEVRO is nepafenac. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nepafenac profile page.

Summary for Tradename: ILEVRO

Suppliers / Packagers: see list2

Pharmacology for Tradename: ILEVRO

Clinical Trials for: ILEVRO

Nepafenac 0.3% Two Study
Status: Completed Condition: Cataract

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Status: Recruiting Condition: Cataract; Retinal Edema; Inflammation

Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema
Status: Active, not recruiting Condition: Diabetic Macular Edema

Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation
Status: Recruiting Condition: Macular Thickening; Macular Edema

Topical Nepafenac as Supplement for Diabetic Macular Edema
Status: Completed Condition: Diabetic Macular Edema

Confirmatory Study Nepafenac 0.3%
Status: Completed Condition: Cataract

Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes
Status: Completed Condition: Intraocular Pressure

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
Status: Completed Condition: Inflammation; Pseudophakia

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
Status: Completed Condition: Macular Edema

A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
Status: Completed Condition: Cataracts

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon Res Ltd
SUSPENSION/DROPS;OPHTHALMIC203491-001Oct 16, 2012RXYes7,947,295<disabled>Y <disabled>
Alcon Res Ltd
SUSPENSION/DROPS;OPHTHALMIC203491-001Oct 16, 2012RXYes<disabled><disabled>
Alcon Res Ltd
SUSPENSION/DROPS;OPHTHALMIC203491-001Oct 16, 2012RXYes6,403,609<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ILEVRO

Country Document Number Publication Date
Japan2011026354Feb 10, 2011
European Patent Office1348427Oct 01, 2003
European Patent Office2361610Aug 31, 2011
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn